Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis
Authors:
- Emanuele CenciniECEmanuele Cencini
- Federica OrsiniFOFederica Orsini
- Marta FranceschiniMFMarta Franceschini
- Sara FredducciSFSara Fredducci
- Mattia BelloMBMattia Bello
- Emanuele PaciniEPEmanuele Pacini
- Marcello BradaschiaMBMarcello Bradaschia
- Anna SicuranzaASAnna Sicuranza
- Chiara CarraraCCChiara Carrara
- Paolo BertelliPBPaolo Bertelli
- Monica BocchiaMBMonica Bocchia
- Alberto FabbriAFAlberto Fabbri
Open Access
- 1 July 2026
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 392
Abstract
After first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), 20–30% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory disease. Semi-quantitative volume parameters on [18F]Fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT), performed at diagnosis, could represent variables with prognostic influence. We retrospectively analyzed 53 consecutive patients, treated between 2016 and 2022. Semi-quantitative metabolic parameters, assessed by the software LIFEx, included total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), Dmax and DmaxVox. All cases received R-CHOP/CHOP-like regimens with curative intent. The International Metabolic Prognostic Index (IMPI) was low in 43/53 cases (81.1%). CR was achieved in 49/53 patients (92.4%); 7/53 (13.2%) relapsed after achieving a CR. For the entire cohort, 2-year PFS and OS were 84.9% and 90.6%, respectively, while 5-year PFS and OS were 65.5% and 77.6%, respectively. IPI score, B symptoms, TMTV, Dmax and DmaxVox were associated with reduced PFS in an exploratory univariate analysis. IPI score was the only variable for which we found a significant association with reduced OS. In this exploratory analysis in a small, event-limited population, we suggest the baseline, semi-quantitative metabolic parameters of PET/CT at diagnosis could contribute to defining tumor burden and to predict PFS for DLBCL patients.Keywords
This publication has 52 references indexed in Scilit:
- Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping riskAnnals of Hematology, 2025
- Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology GuidelineBritish Journal of Haematology, 2025
- Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithmHuman Pathology, 2024
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab eraLeukemia Research, 2016
- Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014